Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial

Nikhil Pai, Jelena Popov, Lee Hill, Emily Hartung, Nikhil Pai, Jelena Popov, Lee Hill, Emily Hartung

Abstract

Introduction: Crohn's disease (CD) is a chronic inflammatory condition with transmural involvement of the gastrointestinal tract. Extraintestinal manifestations are common, and the disease burden on patients and the healthcare system is significant. While treatment options have expanded in recent years, they have mainly focused on dampening the immune response, thus carrying notable risks associated with long-term immunosuppression. Faecal microbiota transplant (FMT) targets inflammatory bowel disease (IBD) by modifying intestinal dysbiosis. Limited adult and paediatric data have demonstrated a favourable response to FMT in IBD; however, no randomised controlled trial has yet been published in paediatrics. This double-blind, randomised, placebo-controlled pilot study will assess feasibility and efficacy outcomes of FMT in a paediatric CD population.

Methods and analysis: Forty-five patients between the ages of 3 and 17 years, with established CD or IBD unclassified, will be enrolled 2:1 to undergo FMT intervention or placebo control. Participants will undergo a colonoscopic infusion to the terminal ileum at baseline, followed by oral capsules two times per week for 6 weeks. Outcomes will be measured throughout the intervention period and 18 weeks of subsequent follow-up. Primary outcomes will assess feasibility, including patient recruitment, sample collection and rates of adverse events. Secondary outcomes will address clinical efficacy, including change in clinical response, change in urine metabolome and change in microbiome.

Ethics and dissemination: Ethics approval from the local hospital research ethics board was obtained at the primary site (McMaster Children's Hospital, Hamilton), with ethics pending at the secondary site (Centre Hospitalier Universitaire-Sainte-Justine, Montréal). RBX7455 and RBX2660 are human donor-sourced, microbiota-based therapeutic formulations. Both RBX7455 and RBX2660 are currently undergoing clinical trials to support potential US Food and Drug Administration approval. Approval to conduct this paediatric clinical trial was obtained from Health Canada's Biologics and Genetic Therapies Directorate. The results of this trial will be published in peer-reviewed journals and will help inform a large, multicentre trial in the future.

Trial registration number: NCT03378167; pre-results.

Keywords: crohn’s disease; faecal microbiota transplant; inflammatory bowel disease; microbiome; oral microbiota capsules; paediatrics.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Protocol flowchart indicating intervention, control and open-label arms. AStrongly favouring CD as deemed by patient’s primary gastroenterologist; CD, Crohn’s disease; CRP, C reactive protein; fCal, faecal calprotectin; FMT, faecal microbiota transplant; IBD, inflammatory bowel disease; NS, normal saline; OMC, oral microbiota capsule; OPC, oral placebo capsule; PCDAI, Paediatric Crohn’s Disease Activity Index .
Figure 2
Figure 2
Collection timepoints of clinical study outcomes.

References

    1. Bessissow T, Reinglas J, Aruljothy A, et al. . Endoscopic management of Crohn's strictures. World J Gastroenterol 2018;24:1859–67. 10.3748/wjg.v24.i17.1859
    1. Lowe A-M, Roy P-O, B-Poulin M, et al. . Epidemiology of Crohn's disease in Québec, Canada. Inflamm Bowel Dis 2009;15:429–35. 10.1002/ibd.20756
    1. Benchimol EI, Guttmann A, Griffiths AM, et al. . Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009;58:1490–7. 10.1136/gut.2009.188383
    1. Rocchi A, Benchimol EI, Bernstein CN, et al. . Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2012;26:811–7. 10.1155/2012/984575
    1. Talley NJ, Abreu MT, Achkar J-P, et al. . An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106:S2–25. 10.1038/ajg.2011.58
    1. Mann G, Greer M-L, Nadel H. Paediatric Crohn’s Disease : Greer M-L, Nadel H, Mann G, Crohn’s Disease. Cham: Springer International Publishing, 2015: 123–42.
    1. Hyams JS, Davis P, Grancher K, et al. . Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81–8. 10.1016/S0022-3476(96)70193-2
    1. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. . Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423–39. 10.1002/ibd.21349
    1. El Mouzan M, Al Mofarreh MA, Saadah OI. Impact of pediatric inflammatory bowel disease on linear growth: data from a national cohort study in Saudi Arabia. Saudi J Gastroenterol 2016;22:396–108. 10.4103/1319-3767.191147
    1. Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol 2014;11:601–10. 10.1038/nrgastro.2014.102
    1. Agace WW, McCoy KD. Regionalized development and maintenance of the intestinal adaptive immune landscape. Immunity 2017;46:532–48. 10.1016/j.immuni.2017.04.004
    1. Pabst O, Pires da Cunha A, Weiner HL. Mechanisms of oral tolerance to soluble protein antigens. In: Mucosal Immunology. Elsevier 2015:831–48.
    1. Bischoff SC, Sampson HA. Food allergy and gastrointestinal syndromes In: Allergy: expert consult online and print. 4th edn, 2012: 297–303.
    1. Murch S. Pediatric gastrointestinal and liver disease. (Murch S, ED.).. Elsevier 2011.
    1. Horjus Talabur Horje CS, Smids C, Meijer JWR, et al. . High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients. Clin Exp Immunol 2017;188:163–73. 10.1111/cei.12918
    1. McNamee EN, Rivera-Nieves J. Ectopic tertiary lymphoid tissue in inflammatory bowel disease: protective or Provocateur? Front Immunol 2016;7 10.3389/fimmu.2016.00308
    1. Dignass A, Van Assche G, Lindsay JO, et al. . The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28–62. 10.1016/j.crohns.2009.12.002
    1. Vernier–Massouille G, Balde M, Salleron J, et al. . Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106–13. 10.1053/j.gastro.2008.06.079
    1. von Roon AC, Karamountzos L, Purkayastha S, et al. . Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13. 10.1111/j.1572-0241.2007.01126.x
    1. Cunliffe RN, Scott BB. Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:647–62. 10.1046/j.1365-2036.2002.01216.x
    1. Tavernier N, Fumery M, Peyrin-Biroulet L, et al. . Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:847–53. 10.1111/apt.12478
    1. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. . Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010;105:1893–900. 10.1038/ajg.2010.20
    1. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006;12:697–707. 10.1097/00054725-200608000-00005
    1. Pai N, Popov J. Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial. BMJ Open 2017;7:e016698 10.1136/bmjopen-2017-016698
    1. Haberman Y, Tickle TL, Dexheimer PJ, et al. . Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 2014;124:3617–33. 10.1172/JCI75436
    1. Gevers D, Kugathasan S, Denson LA, et al. . The Treatment-Naive Microbiome in New-Onset Crohn’s Disease. Cell Host Microbe 2014;15:382–92. 10.1016/j.chom.2014.02.005
    1. Conte MP, Schippa S, Zamboni I, et al. . Gut-Associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006;55:1760–7. 10.1136/gut.2005.078824
    1. Tedelind S, Westberg F, Kjerrulf M, et al. . Anti-Inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007;13:2826–32. 10.3748/wjg.v13.i20.2826
    1. Machiels K, Joossens M, Sabino J, et al. . A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014;63:1275–83. 10.1136/gutjnl-2013-304833
    1. Kassam Z, Lee CH, Yuan Y, et al. . Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500–8. 10.1038/ajg.2013.59
    1. Moayyedi P, Surette MG, Kim PT, et al. . Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–9. 10.1053/j.gastro.2015.04.001
    1. Paramsothy S, Kamm MA, Kaakoush NO, et al. . Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017;389:1218–28. 10.1016/S0140-6736(17)30182-4
    1. Costello SP, Soo W, Bryant RV, et al. . Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 2017;46:213–24. 10.1111/apt.14173
    1. Narula N, Kassam Z, Yuan Y, et al. . Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 2017;23:1702–9. 10.1097/MIB.0000000000001228
    1. Rossen NG, Fuentes S, van der Spek MJ, et al. . Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110–8. 10.1053/j.gastro.2015.03.045
    1. Goyal A, Yeh A, Bush BR, et al. . Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease. Inflamm Bowel Dis 2018;24:410–21. 10.1093/ibd/izx035
    1. Suskind DL, Singh N, Nielson H, et al. . Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2015;60:27–9. 10.1097/MPG.0000000000000544
    1. Suskind DL, Brittnacher MJ, Wahbeh G, et al. . Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 2015;21:556–63. 10.1097/MIB.0000000000000307
    1. Kellermayer R, Nagy-Szakal D, Harris RA, et al. . Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. Am J Gastroenterol 2015;110:604–6. 10.1038/ajg.2015.19
    1. Kunde S, Pham A, Bonczyk S, et al. . Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013;56:597–601. 10.1097/MPG.0b013e318292fa0d
    1. Wang H, Cui B, Li Q, et al. . The Safety of Fecal Microbiota Transplantation for Crohn’s Disease: Findings from A Long-Term Study. Adv Ther 2018;35:1935–44. 10.1007/s12325-018-0800-3
    1. Zhang F. Standardized Fecal Microbiota Transplantation for Crohn’s Diseases (NCT01793831). U.S. National Library of Medicine: Clinical Trials.
    1. Youngster I, Gerding DN. Editorial: making fecal microbiota transplantation easier to swallow: freeze-dried preparation for recurrent Clostridium difficile infections. Am J Gastroenterol 2017;112:948–50. 10.1038/ajg.2017.91
    1. Youngster I, Mahabamunuge J, Systrom HK, et al. . Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med 2016;14 10.1186/s12916-016-0680-9
    1. Kao D, Roach B, Silva M, et al. . Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection. JAMA 2017;318 10.1001/jama.2017.17077
    1. Jiang Z-D, Jenq RR, Ajami NJ, et al. . Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. PLoS One 2018;13:e0205064 10.1371/journal.pone.0205064
    1. Rebiotix RBX7455 clinical trials. Available: [Accessed 1 Jul 2019].
    1. OpenBiome. Available: [Accessed 1 Jul 2019].
    1. CIDsCaNN The Canadian children inflammatory bowel disease network. Available:
    1. Rebiotix Microbiota restoration therapy. Available: [Accessed 1 Jul 2019].
    1. Turner D, Otley AR, Mack D, et al. . Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423–32. 10.1053/j.gastro.2007.05.029
    1. Turner D, Griffiths AM, Walters TD, et al. . Mathematical weighting of the pediatric Crohnʼs disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012;18:55–62. 10.1002/ibd.21649
    1. Turner D, Levine A, Walters TD, et al. . Which PCDAI version best reflects intestinal inflammation in pediatric Crohn disease? J Pediatr Gastroenterol Nutr 2017;64:254–60. 10.1097/MPG.0000000000001227
    1. RBX R. Clinical Trials;2660
    1. Daperno M, D'Haens G, Van Assche G, et al. . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505–12. 10.1016/S0016-5107(04)01878-4
    1. Hyams JS, Ferry GD, Mandel FS, et al. . Development and validation of a pediatric Crohnʼs disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–47 10.1097/00005176-199105000-00005
    1. Illumina MiSeqTM system. Available: [Accessed 1 Jul 2019].
    1. National Institutes of Health Nih human microbiome project. National Institutes of health. Available: [Accessed 1 Jul 2019].
    1. Pai N, Popov J. Pediatric fecal microbiota transplant for ulcerative colitis (PediFETCh) (NCT02487238). U.S. National library of medicine: clinical trials.
    1. Government of Canada Biologics and genetic therapies Directorate. health products and food branch, 2019. Available: [Accessed 1 Jul 2019].
    1. Cammarota G, Ianiro G, Tilg H, et al. . European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569–80. 10.1136/gutjnl-2016-313017
    1. Thakkar K, El-Serag HB, Mattek N, et al. . Complications of pediatric colonoscopy: a five-year multicenter experience. Clin Gastroenterol Hepatol 2008;6:515–20. 10.1016/j.cgh.2008.01.007
    1. General Assembly of the World Medical Association World Medical association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 2014;81:14–18.
    1. Tri-Council policy statement: ethical conduct for research involving humans. Available:
    1. Hamilton Integrated Research Ethics Board Forms & Downloads. Available: [Accessed 15 Jun 2018].
    1. Research Centre of the Sainte-Justine University Hospital Research ethics. Available: [Accessed 1 Jul 2019].
    1. Pai N, Hill L, Popov J. PediCRaFT: Pediatric Crohn’s Disease Fecal Transplant Trial (PediCRaFT) (NCT03378167). U.S. National Library of Medicine: Clinical Trials.
    1. National Institutes of Health Hmp data release and resource sharing guidelines for human microbiome project data production grants. Available: [Accessed 22 Oct 2017].
    1. Suskind D. Bacteriotherapy in pediatric inflammatory bowel disease (NCT01757964). U.S. National library of medicine: clinical trials.
    1. Goyal A. Fecal microbiota transplantation in pediatric patients (FMT) (NCT02108821). U.S. National library of medicine: clinical trials.
    1. Kahn S. Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn’s Colitis (NCT02330211). U.S. National Library of Medicine: Clinical Trials.
    1. Hospital XFMMUXDD. Available: . [Accessed 1 Jul 2019].
    1. Michail S, Leong R. FMT in Pediatric Crohn’s Disease (FMTPCD) (NCT03194529). U.S. National Library of Medicine: Clinical Trials 2017.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する